215 related articles for article (PubMed ID: 29991024)
1. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
Raymond E; Kulke MH; Qin S; Yu X; Schenker M; Cubillo A; Lou W; Tomasek J; Thiis-Evensen E; Xu JM; Croitoru AE; Khasraw M; Sedlackova E; Borbath I; Ruff P; Oberstein PE; Ito T; Jia L; Hammel P; Shen L; Shrikhande SV; Shen Y; Sufliarsky J; Khan GN; Morizane C; Galdy S; Khosravan R; Fernandez KC; Rosbrook B; Fazio N
Neuroendocrinology; 2018; 107(3):237-245. PubMed ID: 29991024
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
Ito T; Tori M; Hashigaki S; Kimura N; Sato K; Ohki E; Sawaki A; Okusaka T
Jpn J Clin Oncol; 2019 Apr; 49(4):354-360. PubMed ID: 30834940
[TBL] [Abstract][Full Text] [Related]
3. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
Solis-Hernandez MP; Fernandez Del Valle A; Carmona-Bayonas A; Garcia-Carbonero R; Custodio A; Benavent M; Alonso Gordoa T; Nuñez-Valdovino B; Sanchez Canovas M; Matos I; Alonso V; Lopez C; Viudez A; Izquierdo M; Calvo-Temprano D; Grande E; Capdevila J; Jimenez-Fonseca P
Br J Cancer; 2019 Oct; 121(7):537-544. PubMed ID: 31477779
[TBL] [Abstract][Full Text] [Related]
4. Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib.
Fazio N; Kulke M; Rosbrook B; Fernandez K; Raymond E
Target Oncol; 2021 Jan; 16(1):27-35. PubMed ID: 33411058
[TBL] [Abstract][Full Text] [Related]
5. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
Lamarca A; Barriuso J; Kulke M; Borbath I; Lenz HJ; Raoul JL; Meropol NJ; Lombard-Bohas C; Posey J; Faivre S; Raymond E; Valle JW
Br J Cancer; 2018 Jan; 118(2):181-188. PubMed ID: 29161241
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data.
Valle JW; Borbath I; Rosbrook B; Fernandez K; Raymond E
Future Oncol; 2019 Apr; 15(11):1219-1230. PubMed ID: 30701988
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
8. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
Blumenthal GM; Cortazar P; Zhang JJ; Tang S; Sridhara R; Murgo A; Justice R; Pazdur R
Oncologist; 2012; 17(8):1108-13. PubMed ID: 22836448
[TBL] [Abstract][Full Text] [Related]
9. Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study.
Sato K; Toyoshima Y; Moriyama S; Endo Y; Ito T; Ohki E
Cancer Chemother Pharmacol; 2019 Jan; 83(1):201-207. PubMed ID: 30413868
[TBL] [Abstract][Full Text] [Related]
10. Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors.
Lee L; Ito T; Igarashi H; Miki M; Fujimori N; Kawabe K; Jensen RT; Ogawa Y
Cancer Chemother Pharmacol; 2018 Jan; 81(1):163-169. PubMed ID: 29164297
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.
Rinzivillo M; Fazio N; Pusceddu S; Spallanzani A; Ibrahim T; Campana D; Marconcini R; Partelli S; Badalamenti G; Brizzi MP; Catena L; Schinzari G; Carnaghi C; Berardi R; Faggiano A; Antonuzzo L; Spada F; Gritti S; Femia D; Gelsomino F; Bongiovanni A; Ricci S; Brighi N; Falconi M; Delle Fave G; Panzuto F
Pancreatology; 2018 Mar; 18(2):198-203. PubMed ID: 29361429
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
Ito T; Okusaka T; Nishida T; Yamao K; Igarashi H; Morizane C; Kondo S; Mizuno N; Hara K; Sawaki A; Hashigaki S; Kimura N; Murakami M; Ohki E; Chao RC; Imamura M
Invest New Drugs; 2013 Oct; 31(5):1265-74. PubMed ID: 23269537
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
Grande E; Rodriguez-Antona C; López C; Alonso-Gordoa T; Benavent M; Capdevila J; Teulé A; Custodio A; Sevilla I; Hernando J; Gajate P; Molina-Cerrillo J; Díez JJ; Santos M; Lanillos J; García-Carbonero R
Oncologist; 2021 Nov; 26(11):941-949. PubMed ID: 34190375
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib-Induced Hypothyroidism and Survival in Pancreatic Neuroendocrine Tumors.
Mathew A; Führer D; Lahner H
Horm Metab Res; 2021 Dec; 53(12):794-800. PubMed ID: 34891209
[TBL] [Abstract][Full Text] [Related]
15. Activity of sunitinib in patients with advanced neuroendocrine tumors.
Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the safety and efficiency of sunitinib malate in metastatic neuroendocrine tumours of the pancreas (NEN G1/G2) depending on the number and type of earlier therapeutic lines - initial report.
Wachuła E; Ćwikła JB; Rogowski W; Boratyn-Nowicka A; Szabłowska-Siwik S; Piątek M; Zemczak A; Michalik B; Jarząb B; Nawrocki S; Kos-Kudła B
Endokrynol Pol; 2014; 65(6):472-8. PubMed ID: 25554616
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.
Faivre S; Niccoli P; Castellano D; Valle JW; Hammel P; Raoul JL; Vinik A; Van Cutsem E; Bang YJ; Lee SH; Borbath I; Lombard-Bohas C; Metrakos P; Smith D; Chen JS; Ruszniewski P; Seitz JF; Patyna S; Lu DR; Ishak KJ; Raymond E
Ann Oncol; 2017 Feb; 28(2):339-343. PubMed ID: 27836885
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
[TBL] [Abstract][Full Text] [Related]
20. Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison.
Ishak KJ; Rael M; Hicks M; Mittal S; Eatock M; Valle JW
J Comp Eff Res; 2018 Oct; 7(10):947-958. PubMed ID: 30168349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]